Nagalakshmi Nadiminty, Ph.D.
Associate Professor
Dept.听 Urology & Cell and Cancer Biology
nagalakshmi.nadiminty@utoledo.edu
听EDUCATION:
1992听听听听听听听听听听听听听听听听听听听听听听B.Sc.听听听听听听听听听听听听听听听听 Biology, Andhra University, Visakhapatnam,
India
1994听听听听听听听听听听听听听听听听听听听听听听M.Sc.听听听听听听听听听听听听听听听 Applied Microbiology, SPM Visva Vidyalayam,
Tiruptai, India
2001听听听听听听听听听听 听听听听听听听听听听 Ph.D.听听听听听听听听听听听听听听听听Life Sciences, University of Hyderabad,
Hyderabad, India听
2001-2002听听听听听听听听听 Postdoc听听听听听听听听听听 AMC Cancer Research Center, Denver, CO
2002-2004听听听听听听听听听 Postdoc听听听听听听听听听听 State University of New York at Buffalo, Buffalo,
NY
2004-2007听听听听听听听听听 Postdoc听听听听听听听听听听 Roswell Park Cancer Institute, Buffalo, NY
RESEARCH INTERESTS:
Current research in the Nadiminty lab focuses on the molecular mechanisms of cancer
development and progression in urologic malignancies. Urologic malignancies such as
prostate, bladder, and renal cancers account for significant mortality and morbidity
as well as health care related expenses in the U.S.听
Prostate cancer: Castration-resistant prostate cancer (CRPC) is often treated with anti-androgens
such as enzalutamide and androgen synthesis inhibitors such as abiraterone but therapy
is often complicated by primary or acquired resistance and the mechanisms are mostly
unknown. Dr. Nadiminty's lab aims to elucidate the molecular mechanisms of resistance
to approved therapeutics such as enzalutamide or abiraterone.听Ultimate goals are to
identify combination treatments to improve the efficacy of enzalutamide or abiraterone,
and the development of novel therapeutics and biomarkers.
Bladder cancer: Most cases of bladder cancer present as non-muscle-invasive cancers (NMIBC), a significant
proportion of which progress to muscle-invasive disease (MIBC). MIBCs are often treated
with toxic platinum-based therapeutic regimens; however, many patients are not eligible
due to comorbidities. Even though immunotherapeutics have emerged as new therapies
in recent years, they are not effective in all patients.听Our focus is on the elucidation
of novel molecular signatures, biomarkers, and combination therapies for the management
of bladder cancer.
Renal cancer: Renal cell carcinoma presents as clear-cell RCC, papillary RCC, or chromophobe RCC.
Clear-cell RCC accounts for 80% of RCC. Surgical resection and tyrosine kinase (angiogenesis)
and mTOR inhibitors have been the mainstay of RCC treatment for several years. However,
prognosis for recurrent metastatic RCC is generally poor.听Our aim is to develop combinatorial
strategies to better target RCC subsets to improve personalized medicine.听Current
emphasis is on targeting cancer cell metabolism to improve the efficacy of approved
therapies.
Ongoing Research Support
PC190332, Department of Defense PCRP Idea Development Award-Established Investigator听
Nadiminty (PI)听听听听听听听听听听听听听听听听听听听听听听
09/01/2020-08/31/2023
Tumor metabolism as the Achilles鈥� heel in prostate cancer
Completed Research Support
1R03CA198696-01A1, National Cancer Institute
Nadiminty (PI)
09/22/2017-08/31/2020
Alteration of the miR-Let-7c:Lin28 ratio as a predictor of therapy resistance in Prostate
Cancer
1R21CA202404-01A1, National Cancer Institute
Nadiminty (PI)
07/01/2016-06/30/2020
MicroRNAs modulate therapy resistance in prostate cancer
PC100502, Department of Defense PCRP Idea Development Award-New Investigator
Nadiminty (PI)
07/01/2011-06/30/2015
Novel functions of NF-kappaB2/p52 in androgen receptor signaling in CRPC
UC Davis Academic Federation
Nadiminty (PI)
01/01/2011-12/31/2012
Loss of miR-let-7c as a predictor of castration resistance in prostate cancer
American Cancer Society
Institutional Research Grant
Nadiminty (PI)
01/01/2011鈥�12/31/11
Regulation of the Lin28/miR-let-7c axis by NF kappaB2/p52 in prostate cancer听
RECENT PUBLICATIONS:听听
听STUDENT OPENINGS:听 Currently accepting Ph.D., M.D./Ph.D., M.S.M.D. students
听